



PRESS RELEASE

4 December 2008

ENIGMA DIAGNOSTICS ANNOUNCES ISO 9001:2000 CERTIFICATION

Porton Down, UK & San Francisco, CA – Enigma Diagnostics, the decentralized and point-of-care molecular diagnostics company, announced today the successful achievement of ISO 9001:2000 registration from The British Standards Institute.

The award of this internationally recognized standard demonstrates a Quality Management System (QMS) that consistently meets customer and regulatory requirements for the design, development and manufacture of Enigma's rapid diagnostic instruments.

"I am pleased to announce the successful award of this certification," stated John McKinley, Chairman of Enigma Diagnostics. "Enigma is committed to continuous improvement and will be subject to ongoing assessments by an independent, externally recognized body."

-ENDS-

Contacts

UK Contact:

Enigma Diagnostics

Deborah Cordingley

deborah.cordingley@enigmadiagnostics.com

+44 1980 590131

US Contacts:

Richard Lewis Communications, Inc.

212-827-0020

Megan Dubrowski - Media

mdubrowski@rlcinc.com

Cecelia Heer - Investors

cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK-based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

PRESS RELEASE



Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralized and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion dollar markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licenses from Applied Biosystems and Celera Licences for the commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including U.S., EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com